| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 3/19/2024, p578-578, 1p |
| Abstrakt: |
A new report from AstraZeneca discusses the potential benefits of combining the ATR inhibitor ceralasertib with the PD-L1 antibody durvalumab in melanoma and lung cancer patients who have not responded to immunotherapy. The study found that intermittent treatment with ceralasertib led to antitumor activity and improved T-cell function, which was linked to changes in the tumor microenvironment. The research suggests that ATR inhibition may have broader immunomodulatory effects and could enhance the efficacy of cancer checkpoint immunotherapy. Further details can be found in the article "The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment" published in Nature Communications. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
